DataMEDS AI, Inc. (NASDAQ:MEDS) has announced that its pharmacy subsidiary, Corexa Health, has entered into a commercial supply agreement covering bulk drug substances and active pharmaceutical ingredients (APIs) for six peptides, as the company prepares to expand its compounded prescription offerings.
The agreement covers BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, which were the subject of recommendations by the US Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) during its July 23–24, 2026 meeting.
DataMEDS said Corexa Pharmacy intends to begin dispensing prescriptions for the compounded peptides in November 2026.
The company emphasised that the six substances are not FDA-approved medicines and have not been evaluated by the agency for safety or effectiveness.
The commercial agreement is intended to provide Corexa Health with access to the bulk drug substances and APIs required for preparing the six peptide formulations.
The substances covered by the arrangement are BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax.
According to DataMEDS, the agreement follows recommendations made by the FDA’s Pharmacy Compounding Advisory Committee at its July 2026 meeting.
The company plans to use the supply arrangement to support prescription dispensing through Corexa Pharmacy, with operations expected to begin during November.
Pharmaceutical compounding involves preparing medications for individual patients based on prescriptions, rather than manufacturing standardised, FDA-approved pharmaceutical products.
However, an advisory committee recommendation does not constitute FDA approval, and the six peptides remain unapproved by the agency.
DataMEDS also outlined plans to incorporate safety monitoring into its proposed peptide distribution activities.
The company intends to use its Health Lives Here mobile application to collect and report safety-related information associated with the compounded prescriptions.
According to DataMEDS, the initiative will operate under the US Department of Health and Human Services’ Enforcement Discretion Policy, published in the Federal Register on October 30, 2026.
The proposed data collection process is intended to provide information about the use of the compounded products as the company develops its pharmacy operations.
However, the announcement did not disclose specific safety monitoring procedures, expected patient participation levels or the type of information that will be collected.
The company also did not provide clinical evidence establishing the safety or efficacy of the six peptides.
DataMEDS plans to use its existing distribution capabilities to manage the supply of bulk drug substances and APIs.
The company’s distribution division will rely on third-party logistics services and a warehouse facility in Lakeland, Florida, to coordinate product handling and distribution.
The arrangement is intended to support Section 503A compounding pharmacies operating within the company’s network of more than 6,500 independent pharmacies.
Section 503A of the Federal Food, Drug, and Cosmetic Act establishes conditions under which qualifying pharmacies and healthcare professionals may compound medications for individual patients.
DataMEDS said its distribution infrastructure would support the supply requirements of pharmacies participating in its network.
The company did not disclose the financial terms of the agreement, anticipated distribution volumes or the number of pharmacies expected to participate initially.
Gerald Commissiong, Interim Co-Chief Executive Officer of DataMEDS, described the agreement as an opportunity for Corexa to provide physicians with an alternative to peptide products marketed online for research purposes.
Commissiong said the arrangement could allow healthcare professionals to access pharmacy-compounded formulations through an established dispensing channel rather than relying on products sold for research use only.
The company’s strategy is focused on developing a prescription-based distribution model supported by pharmacy operations and supply-chain infrastructure.
However, the proposed dispensing activities remain subject to applicable regulatory requirements, and the company has not announced any FDA approval for the peptides involved.
DataMEDS explicitly acknowledged that the six peptides covered by the supply agreement are compounded drugs and have not received FDA approval.
The company also confirmed that the FDA has not evaluated these substances for safety or efficacy.
This distinction is important because compounded medications are not subject to the same premarket approval process as FDA-approved pharmaceutical products.
Consequently, the announcement should not be interpreted as confirmation that the six peptides have demonstrated clinical effectiveness or that their safety has been established.
Although the company referred to recommendations from the FDA’s Pharmacy Compounding Advisory Committee, those recommendations do not themselves establish approval for commercial pharmaceutical products.
The regulatory status and applicable compounding requirements will remain important considerations as Corexa prepares to begin dispensing prescriptions.
DataMEDS also highlighted the potential growth of the US compounding pharmacy industry as part of the commercial rationale for its expansion.
According to market research firm Precedence Research, the US compounding pharmacy market is projected to increase from approximately $18 billion in 2025 to more than $31 billion by 2035.
The forecast suggests continued expansion in demand for pharmacy-compounded medications over the coming decade.
DataMEDS is seeking to participate in this market through its pharmacy subsidiary, distribution operations and network of independent pharmacies.
However, the market projection does not represent a revenue forecast for DataMEDS or Corexa Health.
The company has not provided financial guidance relating to the peptide supply agreement or quantified its expected contribution to future earnings.
The agreement represents a further development in DataMEDS AI’s plans to expand its pharmacy and pharmaceutical distribution activities.
The company intends to begin dispensing compounded peptide prescriptions in November 2026 while using its Florida distribution infrastructure to support eligible compounding pharmacies.
Its Health Lives Here application is also expected to play a role in collecting and reporting safety information under the regulatory framework cited by the company.
Investors will be monitoring the progress of the planned launch, pharmacy participation, distribution activity and any additional regulatory developments affecting the six peptides.
Although DataMEDS has identified a potential commercial opportunity in the growing compounding pharmacy market, the announcement did not include revenue projections or financial terms.
The six peptides remain unapproved by the FDA, and their safety and efficacy have not been established through FDA evaluation.
DataMEDS AI stock price
| 2 hours | |
| 3 hours | |
| Oct-23 | |
| Oct-22 | |
| Oct-22 | |
| Oct-20 | |
| Oct-16 | |
| Oct-16 | |
| Oct-14 | |
| Oct-13 | |
| Oct-13 | |
| Oct-12 | |
| Oct-12 | |
| Oct-05 | |
| Oct-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite